Embedded Files
Pluvicto is available in the form of a solution at the strength of 27 mCi/1mL administered intravenously by a healthcare professional, once every 6 weeks for up to 6 doses (recommended dose of 7400 mBq)
More info
More info
The solution itself is clear and colourless to slightly yellow.
pH of the solution is 4.5 to 7.0
1 mL of pluvicto contains approximately 1000 mBq of lutetium.
Each mL of solution contains up to 0.312 mmol (7.1 mg) of sodium.
Pluvicto has a shelf life of 120 hours (5 days) following the date and time of calibration.
Excipients
Excipients
Acetic acid
Sodium acetate
Gentisic acid
Sodium ascorbate
Pentetic acid
Water (for injecting)
Storage
Storage
Pluvicto needs to be stored in the original package in order to prevent ionising radiation (lead shielding). Storage of radio-pharmaceuticals should be in accordance with national regulations on radioactive materials. Pluvicto should not be frozen.
For more information on stability click here
For more information on stability click here
Pluvicto has a half-life of 6.647 days. Lutetium-177 vipivotide tetraxetan decays by β- emission to stable hafnium-177 with the most abundant β- (79.3%) having a maximum energy of 0.497 MeV. The average beta energy is approximately 0.13 MeV. Low gamma energy is also emitted, for instance at 113 keV (6.2%) and 208 keV (11%).
As the medication contains a radio-ligand, patients using pluvicto are advised to avoid close contact with children and pregnant women for seven days following administration to reduce the risk of radiation exposure.
Dosing
Dosing
Dosage of pluvicto is dependent on the specific medical condition of the patient, in correspondence with their respective lab tests and response to the treatment.
Dose modifications
Dose modifications
Dose modifications of pluvicto are implemented in accordance to specific adverse drug reactions (ADRs) and include:
Page updated
Google Sites
Report abuse